Oral Rigosertib in Low Risk MDS Patients Refractory to ESAs
Status:
Completed
Trial end date:
2021-05-01
Target enrollment:
Participant gender:
Summary
The study will enroll low risk MDS patients who need red blood cell transfusions and who are
refractory to or are not using erythropoiesis-stimulating agents. The purpose of the study is
to determine whether oral rigosertib treatment results in hematological improvements
according to the 2006 International Working Group criteria in these patients. The study will
also record any side effects that may occur during the study.